{
  "ticker": "JNJ",
  "target_date": "2025-12-05",
  "actual_date": "2025-12-05",
  "collected_at": "2025-12-08T12:37:23.586095",
  "price": {
    "open": 202.98,
    "high": 203.45,
    "low": 200.81,
    "close": 201.92999267578125,
    "volume": 7785300,
    "change_1d_pct": -0.27,
    "change_7d_pct": -2.29,
    "change_30d_pct": 5.58
  },
  "technicals": {
    "rsi_14": 69.39,
    "sma_20": 199.81,
    "sma_50": 192.48,
    "macd": 4.106,
    "macd_signal": 4.419,
    "macd_histogram": -0.313,
    "bb_upper": 212.99,
    "bb_lower": 186.63,
    "price_vs_sma20_pct": 1.06,
    "price_vs_sma50_pct": 4.91,
    "volume_ratio": 0.82
  },
  "fundamentals": {
    "market_cap": 488460517376,
    "pe_ratio": 19.5695,
    "forward_pe": 19.126415,
    "price_to_book": 6.1535196,
    "price_to_sales": 5.300769,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.44,
    "pct_from_52w_low": 44.11
  },
  "macro": {
    "spy": {
      "price": 685.69,
      "change_1d_pct": 0.19,
      "change_7d_pct": 0.88
    },
    "vix": {
      "level": 15.41,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.14
    },
    "dollar_index": {
      "level": 98.99
    },
    "gold": {
      "price": 4212.9
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Johnson & Johnson's INLEXZO\u2122 (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC",
      "source": "Yahoo",
      "datetime": 1764969600,
      "summary": "Johnson & Johnson (NYSE:JNJ) announced today that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study show treatment with gemcitabine intravesical system resulted in high one-year disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) rates in ",
      "url": "https://finnhub.io/api/news?id=5ebc759cb745ad1a82daa9ee31555facb6663538f68d25fc0fec9ec969d489ba"
    },
    {
      "headline": "Guggenheim Maintains Johnson & Johnson (JNJ) Buy Recommendation",
      "source": "Fintel",
      "datetime": 1764943632,
      "summary": "",
      "url": "https://finnhub.io/api/news?id=a39f18095ce6fb9599f5551d6841d6f946c2b3270fb1ee2e37ec85829b83112c"
    },
    {
      "headline": "Wall Street Races to Cut Its Risk From AI\u2019s Borrowing Binge",
      "source": "Yahoo",
      "datetime": 1764934200,
      "summary": "The urgency at banks to shed risk is visible all over credit markets.  The cost of protecting Oracle Corp. debt against default using derivatives has risen to the highest since the Global Financial Crisis.  Morgan Stanley has looked at using a significant risk transfer \u2014 a form of insurance against ",
      "url": "https://finnhub.io/api/news?id=b53eb934d8907f14b6e8428644fad1b49038c8e877893206c665f15693625de2"
    },
    {
      "headline": "Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi",
      "source": "Yahoo",
      "datetime": 1764931320,
      "summary": "Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing industry pressures.",
      "url": "https://finnhub.io/api/news?id=01405f7aafe79c82bd5dae021b1f3e9c1e4d74ba98213aea0d4cd18b20ef66d5"
    },
    {
      "headline": "Johnson & Johnson (JNJ): A\u00a0Bull\u00a0Case Theory",
      "source": "Yahoo",
      "datetime": 1764901546,
      "summary": "We came across a bullish thesis on Johnson & Johnson on Max Dividends\u2019s Substack. In this article, we will summarize the bulls\u2019 thesis on JNJ. Johnson & Johnson\u2019s share was trading at $205.34 as of December 1st. JNJ\u2019s trailing and forward P/E were 19.99 and 17.99 respectively according to Yahoo Fina",
      "url": "https://finnhub.io/api/news?id=48b55c02897fd5ba21e468ade6eb879e41762b0a6c89794d58c681a9002c9906"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-12-01",
      "description": "xslF345X05/wk-form4_1764623736.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000211/xslF345X05/wk-form4_1764623736.xml"
    },
    {
      "form": "4",
      "date": "2025-12-01",
      "description": "xslF345X05/ownership.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000119312525303876/xslF345X05/ownership.xml"
    },
    {
      "form": "4",
      "date": "2025-11-25",
      "description": "xslF345X05/ownership.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000119312525296047/xslF345X05/ownership.xml"
    },
    {
      "form": "4",
      "date": "2025-11-14",
      "description": "xslF345X05/ownership.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000119312525282669/xslF345X05/ownership.xml"
    },
    {
      "form": "13F-HR",
      "date": "2025-11-13",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445425000587/xslForm13F_X02/primary_doc.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}